The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: A comparative study on traditional antiepileptic drugs versus oxcarbazepine

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Maschio, Marta ^a   Dinapoli, Loredana ^a   Vidiri, Antonello ^a   Pace, Andrea ^a   Fabi, Alessandra ^a   Pompili, Alfredo ^a   Carapella, Maria Carmine ^a   Jandolo, Bruno ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN TUMOR; CLINICAL ARTICLE; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; HEADACHE; HUMAN; LIVER TOXICITY; MALE; MONOTHERAPY; PERIARTHRITIS; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RASH; SEIZURE; SIMPLE PARTIAL SEIZURE; SOMNOLENCE; TONIC CLONIC SEIZURE; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BRAIN NEOPLASMS; CARBAMAZEPINE; EPILEPSY; HUMANS; MIDDLE AGED;

EID: 66649097854     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-60     Document Type: Article

References (32)

1. Optimizing therapy of seizures in patients with brain tumors. CJ Vecht M van Breemen, Neurology 2006 67 12 Suppl 4 S10 S13 17190914
2. Epileptic seizures during follow-up of patients treated for primary brain tumors. J Hildebrand C Lecaille J Perennes JY Delattre, Neurology 2005 65 212 215 10.1212/01.wnl.0000168903.09277.8f 16043788
3. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. MJ Glantz BF Cole PA Forsyth LD Recht PY Wen MC Chamberlain SA Grossman JG Cairncross, Neurology 2000 54 1886 1893 10822423
4. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. D Aguiar R Pazo I Durán J Terrasa A Arrivi H Manzano J Martín J Rifá J Neurooncol 2004 66 345 350 10.1023/B:NEON.0000014538.31561.bc 15015667
5. Comparison and predictors of rash associated with 15 antiepileptic drugs. H Arif R Buchsbaum D Weintraub S Koyfman C Salas-Humara CW Bazil SR Resor Jr LJ Hirsch, Neurology 2007 68 1701 1709 10.1212/01.wnl.0000261917.83337.db 17502552
6. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. M Klein NH Engelberts HM van der Ploeg DG Kasteleijn-Nolst Trenité NK Aaronson MJ Taphoorn H Baaijen WP Vandertop M Muller TJ Postma JJ Heimans, Ann Neurol 2003 54 514 520 10.1002/ana.10712 14520665
7. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. MS van Breemen EB Wilms CJ Vecht, Lancet Neurol 2007 6 421 430 10.1016/S1474-4422(07)70103-5 17434097
8. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. JA French AR Kugler JL Robbins LE Knapp EA Garofalo, Neurology 2003 60 1631 1637 12771254 (Pubitemid 36618090)
9. Levetiracetam therapy in patients with brain tumour and epilepsy. M Maschio F Albani A Baruzzi A Zarabla L Dinapoli A Pace A Pompili CM Carapella E Occhipinti B Jandolo, J Neurooncol 2006 80 97 100 10.1007/s11060-006-9162-9 16685465
10. Outcome and tolerability of topiramate in brain tumor associated epilepsy. M Maschio L Dinapoli A Zarabla A Pompili CM Carapella A Pace D Giannarelli E Occhipinti B Jandolo, J Neurooncol 2008 86 61 70 10.1007/s11060-007-9430-3 17598071
11. Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. AM Mauro C Bomprezzi S Morresi L Provinciali F Formica M Iacoangeli M Scerrati, J Neurooncol 2007 81 279 285 10.1007/s11060-006-9229-7 16944312
12. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. HB Newton SA Goldlust D Pearl, J Neurooncol 2006 78 99 102 10.1007/s11060-005-9070-4 16541329
13. Add-on gabapentin for refractory seizures in patients with brain tumours. JR Perry C Sawka, Can J Neurol Sci 1996 23 128 131 8738926 (Pubitemid 26186481)
14. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. TF Cloughesy PY Wen HI Robins SM Chang MD Groves KL Fink L Junck D Schiff L Abrey MR Gilbert F Lieberman J Kuhn LM DeAngelis M Mehta JJ Raizer WK Yung K Aldape J Wright KR Lamborn MD Prados, J Clin Oncol 2006 24 3651 3656 10.1200/JCO.2006.06.2323 16877733
15. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. JG Kuhn, Oncology 2002 16 33 40 12199631
16. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. S Oberndorfer M Piribauer C Marosi H Lahrmann P Hitzenberger W Grisold, J Neurooncol 2005 72 255 260 10.1007/s11060-004-2338-2 15937649
17. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. KR Crews CF Stewart D Jones-Wallace SJ Thompson PJ Houghton RL Heideman M Fouladi DC Bowers MM Chintagumpala A Gajjar, Clin Cancer Res 2002 8 2202 2209 12114421 (Pubitemid 34753591)
18. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. SA Grossman F Hochberg J Fisher TL Chen L Kim R Gregory LB Grochow S Piantadosi, Cancer Chemother Pharmacol 1998 42 118 126 10.1007/s002800050794 9654111
19. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. W Martinez A Ingenito M Blakeslee GL Barkley K McCague J D'Souza, Epilepsy Behav 2006 9 448 456 10.1016/j.yebeh.2006.04.022 16962380
20. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. A Baruzzi F Albani R Riva, Epilepsia 1994 35 suppl 3 14 19 10.1111/j.1528-1157. 1994.tb05939.x
21. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. JG Larkin PJ McKee G Forrest GH Beastall BK Park JI Lowrie P Lloyd MJ Brodie, Br J Clin Pharmacol 1991 31 65 71 2015172
22. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0, DCTD, NCI, NIH, DHHS, December 12, 2003. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcae-index.pdf#search=ctcae
23. Palliative care in patients with primary brain tumors. S Taillibert F Laigle-Donadey M Sanson, Curr Opin Oncol 2004 16 587 592 10.1097/01.cco. 0000142075.75591.02 15627022
24. Management of epileptic seizures. J Hildebrand, Curr Opin Oncol 2004 16 314 317 10.1097/01.cco.0000127720.17558.38 15187884
25. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? G Zaccara A Messori M Cincotta G Burchini, Acta Neurol Scand 2006 114 157 168 10.1111/j.1600-0404.2006.00705.x 16911343
26. Rash from antiepileptic drugs: influence by gender, age, and learning disability. S Alvestad S Lydersen E Brodtkorb, Epilepsia 2007 48 1360 1365 10.1111/j.1528-1167.2007.01109.x 17484761
27. Neuropsychological deficits in brain tumor patients: Effect of location, chronicity, and treatment. CA Meyers, Cancer Bull 1986 38 30 32
28. Neurobehavioral disorders in brain tumor patients: Rehabilitation strategies. CA Meyers C Boake, Cancer Bull 1993 45 362 364 (Pubitemid 23262154)
29. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. L Brunbech A Sabers, Drugs 2002 62 593 604 10.2165/00003495-200262040-00004 11893228 (Pubitemid 34264027)
30. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. K Villikka KT Kivistö H Mäenpää H Joensuu PJ Neuvonen, Clin Pharmacol Ther 1999 66 589 593 10613614 (Pubitemid 30014085)
31. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: A prospective study in adult and elderly patients with newly diagnosed partial epilepsy. EA Dogan BE Usta R Bilgen Y Senol B Aktekin, Epilepsy Behav 2008 13 156 161 10.1016/j.yebeh.2008.02.001 18331816
32. Phase II of primary temozolomide chemotherapy in patients with WHO grade II gliomas. M Brada L Viviers C Abson F Hines J Britton S Ashley S Sardell D Traish A Gonsalves P Wilkins C Westbury, Ann Oncol 2003 14 1715 1721 10.1093/annonc/mdg371 14630674